AllSci News
Acurx and Leiden University Medical Center target first inhibitor-bound MRSA PolC structure
Staten Island, New York-based Acurx Pharmaceuticals (Nasdaq: ACXP) announced a new scientific research partnership with Netherlands-based Leiden University...
Jazz moves on Actio Bio for up to USD 1.3b to enter KCNT1-driven epilepsy market
Jazz Pharmaceuticals (Nasdaq: JAZZ) has agreed to acquire San Diego-based Actio Biosciences, Inc. for USD 820 million upfront plus up to USD 500 million in...
US bill could subject China-to-US pharma licensing deals to national security controls
Category: Science & Innovation Policy | Regulatory Body: U.S. Congress (Senate) | Geography: United States | Policy Instrument: Legislation
Vedanta secures USD 60m ahead of Phase III VE303 recurrent C. difficile readout
Cambridge, Massachusetts-based Vedanta Biosciences, a late clinical-stage company developing microbiome-based oral therapies for gastrointestinal disease,...
Grand Pharma's FAP-targeted imaging agent earns FDA Fast Track designation
China-based Grand Pharmaceutical Group Limited (HKEX: 00512) announced receipt of US FDA Fast Track Designation (FTD) for GPN01530-2, a fibroblast...
Luzhu’s LZ901 shingles vaccine Phase III results published in Nature Communications
Beijing Luzhu Biotechnology Co., Ltd. (HKEX: 02480) announced on August 9 that Phase III clinical trial results for its recombinant herpes zoster vaccine...
Genfleet becomes first to test oral KRAS G12D inhibitor in Phase III for NSCLC
China-based GenFleet Therapeutics (Shanghai) Inc. (HKEX: 02595) announced on August 10 that the first patient has been dosed in Kylin-Flight 01, a...
Scholar Rock shifts apitegromab BLA to second fill-finish site after Catalent FDA inspection
Cambridge, Massachusetts-based Scholar Rock (Nasdaq: SRRK) announced that the FDA review of its biologics license application (BLA) for apitegromab, a...
HanchorBio partners with Taiwan Cancer Moonshot to guide FBDB pipeline with multi-omics biomarkers
HanchorBio, Inc. (TWSE: 7827), the clinical-stage biotechnology company headquartered in Taipei, Shanghai, and the San Francisco Bay Area, announced a...
Stanford researchers use Evo AI models to design novel bacteriophages against E. coli
Researchers at Stanford University have used a generative AI model to design functional bacteriophages entirely from scratch, demonstrating for the first...
BeOne Q2'26: RAS-ON ADC unveiled as five solid tumor programs race toward Phase III
BeOne Medicines Q2 2026 earnings call, held on August 5, 2026, was defined by two competing narratives: a deepening evidence base for zanubrutinib...
China accepts NDA for Alebund's phosphate binder AP301 after Phase III success
Alebund Pharmaceuticals (Jiangsu) Limited (HKEX: 09637) announced on August 7, 2026 that China's National Medical Products Administration (NMPA) has...
BioInvent wins FDA Fast Track for BI-1808 after encouraging ovarian cancer data
Sweden-based BioInvent International AB (Nasdaq Stockholm: BINV) announced receipt of US FDA Fast Track Designation for BI-1808, a first-in-class anti-tumor...
Neurocrine advances GLP-1/GIP/glucagon triple agonist into first-in-human obesity study
Neurocrine Biosciences (Nasdaq: NBIX) has dosed the first participants in a Phase I first-in-human study of NBIP-1968, an internally discovered...
Sino Bio's benmelstobart-anlotinib regimen adds new China indication in first-line squamous NSCLC
China's National Medical Products Administration (NMPA) has approved a new first-line regimen for locally advanced or metastatic squamous non-small cell...
The AllSci Brief
Free, systematic R&D and deal news. Daily.